Literature DB >> 26004608

The association of ICAM E469K with cardiovascular characteristics of acromegaly.

E Oguz1, S Tabur, H Akbas, I V Duzen, H Karabag, F Akkafa, M Ozkaya, B Alasehirli.   

Abstract

OBJECTIVE: It has been shown that genetic factors have a role in the development of acromegaly. We aimed to investigate the association between intercellular adhesion molecule (ICAM)-1 E469K polymorphism and some cardiovascular clinical parameters of acromegalic patients. PATIENTS AND METHODS: We included 41 patients with acromegaly and 65 healthy subjects with similar age and sex to the study. Fasting plasma glucose (FPG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG) were analyzed. Genotyping was made by polymerase chain reaction-restriction fragment length polymorphism.
RESULTS: The frequency of genotype and allel ICAM-1 E469K was not significantly different between control and patients (p > 0.05). Systolic blood pressure (SBP), diastolic blood pressure (DBP) and FPG levels were significantly higher, and HDL-C was significantly lower in patients with KK genotypes compared to patients with EE genotype in acromegaly group (p < 0.05).
CONCLUSIONS: This is the first study to investigate the role of ICAM gene polymorphism in acromegaly and its cardiovascular characteristics. ICAM E469K may not be a risk factor for the acromegaly in Turkish population but may be associated with hypertension, higher FPG and lower HDL-C in acromegalic patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26004608

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  1 in total

1.  Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly.

Authors:  Aleksandra Franczak; Katarzyna Kolačkov; Aleksandra Jawiarczyk-Przybyłowska; Marek Bolanowski
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.